Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBIT (2023 - 2025)

Historic EBIT for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' EBIT fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 2881.31%. This contributed to the annual value of -$56.6 million for FY2024, which is 1243.37% down from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' EBIT is -$15.8 million, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' EBIT peaked at -$9.7 million during Q1 2023, and registered a low of -$21.1 million during Q2 2025.
  • Over the past 3 years, Compass Therapeutics' median EBIT value was -$15.0 million (recorded in 2024), while the average stood at -$14.7 million.
  • As far as peak fluctuations go, Compass Therapeutics' EBIT plummeted by 262.45% in 2024, and later tumbled by 4068.91% in 2025.
  • Compass Therapeutics' EBIT (Quarter) stood at -$15.4 million in 2023, then fell by 7.67% to -$16.6 million in 2024, then increased by 4.57% to -$15.8 million in 2025.
  • Its EBIT was -$15.8 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$18.0 million in Q1 2025.